Review Article

An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes

Introduction

An effective drug delivery system is required to deliver drugs safely and effectively. Various carrier systems are being explored but there is a constant search for biocompatible, biodegradable, and stable carrier system with the ability to target specific organs. Fabricating materials for the carrier system are responsible for such properties. Lipids offered biocompatibility and biodegradability which is difficult to achieve with different materials. When these lipid-based systems are used as nanosized carriers they provide such properties which are difficult to attain in their bulk counterparts. Nanostructured lipid carriers (NLCs) are evolved as a novel drug delivery carrier.

NLC has several advantages such as biocompatibility, biodegradability, non-immunogenicity, high drug loading capacity, better stability, controlled drug release, and easy preparation technique with scale-up ability. The advantages offered by these carriers make them ideal carrier for drug delivery. Potential cytotoxicity and chances of irritation due to surfactants are major drawbacks.¹

Scioli Montoto et al² reviewed many articles regarding solid lipid nanoparticles (SLNs) and NLC by searching original publications in English in different databases. They found different therapeutic fields for which nanocarriers are prepared such as cancer, central nervous system (CNS) targeting (neurodegenerative diseases, psychosis, migraine, epilepsy, and depression), Antimicrobials, skin disorders, wounds, injuries, diabetes, antioxidants, non-steroidal anti-inflammatory drug (NSAID) and antihypertensives. The majority of formulations were developed to be delivered through the parenteral route followed by the oral route, cutaneous and transdermal route, nasal route, ocular route, and pulmonary and rectal route. This review focused on the different routes employed for the delivery of drugs, the historical background for the development of NLC along with structure and types of NLC, and different commonly employed manufacturing techniques.

Need for nanostructured lipid carriers

More than 50 years ago AD Bangham discovered “swollen phospholipids” as a model of the cell membrane, which was later termed liposome.³ From there on the spontaneous rearrangement of lipids to form nano colloidal particles have been constantly explored and evolved. Liposomes are established as drug delivery carriers in coming years with excellent properties to deliver drugs safely with increasing bioavailability and reducing toxicity.⁴ In 1995 with the first Food and Drug Administration (FDA) approval of liposomal doxorubicin a new era of lipid-based nanomedicine has been begun. Liposomes provide a safe and effective biodegradable platform for drug delivery. Vesicle-based lipid nanosystem did not meet expectations as a versatile drug carrier due to physiological stability, complex nature of nanomedicine, and cost of such medicine leading to a search for new lipid systems.⁵ Nanoemulsion is among the low-cost alternatives to the vesicle-based system but it is not effective in providing enough stability and safety to drugs.⁶

Due to the shortcomings related to the earlier lipid-based nanosystem, a new class of lipid-based particulate systems emerged as an alternative by combining the advantage offered by liposome, nanoemulsion, and Polymer nanoparticles.¹ In the early 1990s Müller et al independently developed SLNs with different methods, first-generation lipid nanoparticles as a cost-effective and versatile drug delivery system. These lipid-based nanosystems are mainly developed for cosmetics.^7,8 SLN are solid lipid cores enclosed in lipidic and surfactant shells which can encapsulate the drug in a solid lipid matrix core. SLN has several advantages that make them suitable drug carriers for lipophilic drugs. They are physiologically more stable than other lipid-based nanosystems and contain biodegradable material for their fabrication, as well as a scalable fast, and effective manufacturing process.⁹ With a solid lipid core they can be stored for a long time in an aqueous condition which is impossible with liposomes.¹⁰ As solid lipid nanoparticle contains the organized solid lipid core, they have low drug loading capacity, which is a major drawback for efficient drug delivery. Initial burst release and stability issues on long-term storage are also a disadvantage of SLN such as the polymeric transition to crystalline form and drug leakage.¹¹

In 1999 a new second-generation lipid nanoparticle emerged to overcome problems associated with the SLN. NLC is a nanocarrier that has advantages of previous lipidic nanoparticles along with a high drug loading capacity and increased stability than SLN.¹² NLCs have made an entry into the cosmetic market in 2005 due to the properties they offered and now there are around 40 cosmetics products are there in the market. Due to the inherent qualities of NLC and their efficient encapsulation capacity this system has yet to hit the market as a drug delivery system.¹³ contains different types of lipids-based nanocarriers.

Close

Figure 1. Evolution of lipid based nanocarriers

Structure of nanostructured lipid carriers

NLCs as the name suggest are nanosized multiparticulate system in the size range of 50 nm to 500 nm. The particle size distribution of NLC depends on nanoparticles’ manufacturing process and composition. Colloidal in nature this particle resembles the structure of SLN with the main variation being in the core of these nanoparticles.¹⁴ Unlike SLN which contains a solid lipid core in which lipid is arranged in a highly organized fashion, NLC contains lipid liquid along with a solid lipid core which forms an unorganized drug matrix. With this unorganized nature, more drugs can be loaded in the core in addition to stability issues encountered on long-term storage of SLN due to crystallization and drug expulsion is also rectified with NLC.¹¹ NLC’s core is made up of solid lipid and liquid lipid in a 70:30 to 99.9:0.1 ratio, which distorts the NLC core. As the lipophilic molecule is more soluble in liquid lipid and the imperfection caused due to blends of lipid more space is available for drug incorporation in these nanocarriers.¹⁵ All materials used for the formulation of NLC should be considered generally regarded as safe (GRAS), as they should be non-toxic and biocompatible. Choice of lipid in NLC should also be made depending upon drug-lipid compatibility. Along with lipids which are used in a binary mix of solid and liquid lipids, one or a combination of surfactants are used within the range of 1.5% to 5% (w/v) to stabilize the nanosystem.¹⁶ Surfactant forms a coat around the NLC core. Choice of lipid and surfactant plays an important role in determining particle size and physicochemical properties of NLC. The type and number of surfactants is a crucial formulation parameter as using more than one surfactant results in less particle size and crystallinity than a single surfactant system. Two different surfactant results in a more stable system.¹⁷

Variation in lipid content and formulation parameters results in a change in core structure and arrangement of solid lipid and liquid lipid. Three possible variations are classified by Muller et al as three different types of NLC. In the first type (imperfect crystal type), lipid content is low which results in deformation in solid lipid crystalline structure. Different fatty acid triglycerides can be used to modify the imperfection and structure of nanoparticles. Due to the fact, that lipophilic drugs are more soluble in liquid lipid, an increase in lipid concentration results in high drug incorporation. In the second type (Multiple types or oil-in-fat-in-water O/F/W carrier), they contain a high quantity of oil which results in a nano oil-based compartment within the particle resulting in a tiny packet of drug solubilized in liquid lipid. High liquid lipid solubility results in low drug leakage as well as slow drug release from this type of nanoparticles. The third type (Amorphous or non-crystalline type) is formed by blending solid and liquid lipid in a certain way to avoid crystallization of the core. This approach results in low drug expulsion due to the crystallization of the solid core.^18–20 contains different categories of NLC.

Close

Figure 2. Types of nanostructured lipid carriers

Methods of Preparation

There have been several methods reported for preparing NLCs. Various preparation methods are as follows:

1. Hot high-pressure homogenization technique

2. Cold high-pressure homogenization technique

3. High speed/shear homogenization technique

4. Microemulsion

5. Solvent diffusion and evaporation technique

6. Hot melt extrusion

7. Solvent injection technique

Hot high-pressure homogenization

High-pressure homogenization is an energy-intensive and scalable technique to produce nano-sized colloidal systems (NLC, SLN, and nanoemulsions). It uses the top-down approach for the miniaturization of microemulsion particles to nano-size with the help of applied pressure.²¹ In this method, solid lipid was melted, then liquid lipid was added to form a heated lipid phase. Surfactants with or without cosurfactants are added to water to form an aqueous phase. Then the preheated lipid phase is mixed with the heated aqueous phase under constant stirring to create a microemulsion. This hot microemulsion is subjected to a high-pressure homogenizer for size reduction. Various homogenization cycles can be utilized based on the desired particle size. This nanoemulsion is cooled to be converted into NLC.^22,23 Intermediate pressure (1000 bar) for long-time results in small particle size of NLC with less than 100 nm.²⁴ This process is not preferred for drugs or materials which degrade at high temperatures. depicts systematic steps to formulate NLC.

Close

Figure 3. Hot high-pressure homogenization

Cold high-pressure homogenization

Similar to hot high-pressure homogenization this process involves a mixture of lipid phase with a cold aqueous solution maintained at a temperature of approximately in the range of 2^∘C to 6^∘C with constant stirring. This coarse NLC suspension is homogenized with a high-pressure homogenizer at low temperatures. This process is suitable for drugs and materials which cannot be exposed to high temperatures.²⁵

High-speed homogenization

This method of NLC preparation is identical to hot high-pressure homogenization. In this process, high pressure is replaced with a high shear rate. The lipid phase is prepared by mixing liquid lipid in melted solid lipid and the aqueous phase is prepared by mixing surfactant in water. This heated lipid and the aqueous phase are homogenized with a homogenizer at high rotation per minute (rpm) for a long time (10-30 minutes). The resulting solution is cooled at room temperature to form NLC.^26,27 Speed of homogenization linearly affects the particle size of nanocarriers.²⁸ Liquid nanoemulsion before cooling can also be sonicated for 5 minutes using an ultrasonic probe followed by cooling to further reduce the particle size of NLC.²⁹ In some literature melt emulsification method was described in which the same technique was employed with low-speed homogenization and increased sonication time.^30,31 shows a flowchart of steps required to formulate NLC through high-speed homogenization.

Close

Figure 4. High speed homogenization

Microemulsion

In the microemulsion technique, the liquid lipid is added to the molten solid lipid. The resultant solution is mixed with an aqueous phase to form a microemulsion. This microemulsion is rapidly cooled with cold water to form NLC dispersion system. The difference in microemulsion and water dictates the particle size of NLC. This is a simple technique to prepare NLC but requires a high amount of surfactant and cosurfactant.³²

Solvent diffusion and evaporation technique

In this technique, the liquid lipid is added to molten solid lipid which is dissolved in either a single or combination of organic solvents at high temperature. This lipid solution is then added to an aqueous solution containing surfactant with stirring This prepared dispersion is ultrasonicated to produce oil in water nanoemulsion which is cooled down with low stirring until the organic solvent is evaporated.³³ This technique is low energy-intensive and avoids physical stress due to high pressure or shear, but due to the use of organic solvent, an additional step is required to remove the residual toxic solvent.²¹ shows solvent diffusion or solvent evaporation technique for the preparation of NLC.

Close

Figure 5. Solvent diffusion and evaporation technique

Hot melt extrusion technique

The hot melt extrusion technique involves raw material pumping into a barrel, followed by sonication to obtain NLC. In this technique drug and solid lipid, the mixture was introduced in an extruder barrel using the volumetric feeder. Liquid lipid and aqueous solutions were added through a peristaltic pump at extrusion temperature. This mixture was extruded at component melt temperature to form a pre-emulsion. The resultant hot pre-emulsion is further sonicated to reduce NLC particle size.³⁴ shows the steps to prepare NLC by hot melt extrusion technique.

Close

Figure 6. Hot melt extrusion technique

Solvent injection technique

In this technique, the lipid phase is dissolved in a water-miscible solvent or their mixture with aid of heat to melt solid lipid. The resultant organic phase is rapidly injected into an aqueous phase containing surfactant or buffer solution with constant stirring. The solvent is diffused due to lipid precipitation and lipid nanocarrier formation. Particle size depends on solvent diffusion and emulsifier content.²¹ shows steps to prepare NLC by hot melt extrusion technique.

Close

Figure 7. Solvent injection technique

Advantages of NLC

Drug delivery using NLC

NLC have the inherent ability to deliver drugs safely and effectively through different routes. NLC can be employed to treat various ailments that require either localized drug delivery or targeted drug delivery. Along with the application of NLC for the delivery of drugs through different routes, these nanocarriers are also explored for the delivery of genetic material for gene therapy. Following are the examples of different routes employed for drug delivery using NLC.

Delivery through oral route

The oral route is the most preferred route for drug delivery due to the convenience it provides. Drug delivery through the oral route is primarily considered by every formulator due to better patient compliance, easy administration without pain as in the parenteral route, and without assistance with low cost. But several hurdles make drug delivery through the route of choice difficult. Low solubility and permeability are the major challenges along with low stability in the harsh gastric environment leading to the delivery of drugs through a different route or use of carrier system. NLC provides one solution to deliver drugs efficiently through the oral route.³⁵ There are several physiological challenges in the delivery of drug molecules through the oral route. pH gradient across the gastrointestinal tract (GIT) fluid is one of the major hurdles for drug stability as the drug molecule has to pass from the acidic environment in the stomach (pH 1.5-3.5) to the basic condition in the intestine (pH 5-8). Gastric and intestinal enzymes and secretions such as pepsin, bile, trypsin, etc. lead to further degradation of the drug in GIT. Along with this, sticky mucus covering the entire GIT makes the situation worse for the drug to penetrate this physiological barrier. Epithelial barrier, p-glycoprotein efflux pump in the gut wall, and first-pass metabolism make the oral delivery of most of the drug challenging task.^36,37

Lipid-based nanocarriers when delivered orally can be absorbed through various mechanisms such as transcellular transport, M cell-mediated transport, carrier-mediated transport, or by mucoadhesion. Unlike small and hydrophilic molecule which follows the paracellular pathway along the tight junction of enterocytes in the intestine, lipophilic drug and nanocarriers are transported through transcellular pathways. Transcellular absorption of the drug as well as nanocarriers is carried by endocytosis which can be occurred via phagocytosis through M cells. These M cells are the third most abundant cell type in the intestine and they are present in gut-associated lymphoid tissue (GALT) or Payer’s Patch. M cells do not contain a thick layer of mucus and are present to detect antigen and deliver molecules through the lymphatic system. Endocytosis is generally favored for naturally occurring molecules and the product made with the natural molecule, Thus NLC which contains lipid is favored for delivery of drugs through endocytosis.^36,38 Gastric lipase and pancreatic lipase result in the breakdown of dietary triglyceride as well as triglyceride present in the lipid-based formulation, into di- and monoglycerides and fatty acids. The presence of exogenous lipid in the small intestine stimulates the secretion of bile salt, phospholipid, and cholesterol which arrange or make micelle or vesicular complex with exogenous lipid and facilitate absorption of these complexes.³⁹ Attempts are being made to formulate NLC with bile salt such as sodium glycocholate, which increases many-fold increase in bioavailability.⁴⁰ Formulation of NLC which forms a complex with bile salt and is uptake by the lymphatic system result in bypassing first-pass metabolism, which is a major hurdle for oral delivery of drugs with extensive hepatic metabolism.

Another mechanism by which drug absorption will be increased is mucoadhesion. Mucoadhesion due to adherence of nanocarriers results in higher residence time of the drug in the GIT tract and an increase in time for the drug to be solubilized and absorbed through GI lining. Nanocarrier has a general tendency of adherence to the mucus layer on epithelial surface but a coating of the mucoadhesive layer further increases the mucoadhesion of NLC.⁴¹ Chitosan a natural mucoadhesive polysaccharide is frequently used to coat NLC particles, this coating results in double bioavailability than non-coated NLC.⁴² Various other materials are used to increase bioavailability and to sustain the release of the drug.

As nearly half of the drugs being developed in recent years have low water solubility and the majority of nanomedicine that are being marketed or in the development phase are being delivered through the parenteral route. The parenteral route is not suitable for chronic conditions in which self-administration is preferred and conditions in which nontargeting is required such as hypertension, diabetes, infections, and chronic pain management. The oral route is also preferred in conditions that need local delivery of drugs in gastric conditions and drugs which are needed to be targeted to the liver.⁴³ Table 1 contains different NLC formulations which are administered through oral route

Delivery through transdermal route

Skin is a choice for drug delivery in many localized skin diseases and infections as well as delivery of drugs in a sustained and controlled fashion for the management of pain or wound healing. Skin being an easily accessible organ with a large surface area makes drug delivery through this route achievable without pain and undesired systemic side effects. Drug delivery through this route is mainly divided into dermal for localized effect and transdermal for deep skin penetration.⁵² Skin is a metabolically active organ with the main function of protecting the body from external dangers. Skin act as a barrier for external microorganisms, chemicals, or other molecules which try to enter the body and may create harm. This barrier function of the skin makes it difficult for therapeutically active molecules to directly enter the body.

Anatomically skin is divided into the Epidermis, which contains an outer layer termed as stratum corneum with keratinized cells. And inner layer of the dermis and subcutaneous fat tissue. The outermost layer which is stratum corneum is the main barrier that is less permeable to avoid water and electrolyte loss. Brick and mortar-based multilayered arrangement of flattened corneocytes with extracellular lipid make penetration of large molecules impossible ( > 500 Da).⁵³ Along with a less penetrable outer layer, other defensive features such as low skin pH, the presence of metabolizing enzymes make the situation difficult for many drugs.⁵⁴

Percutaneous absorption of a drug or other molecules is possible through pathways: First, the Transepidermal pathway includes diffusion of lipophilic solute through intercellular lipid domains or intracellular permeation of solute through imperfections in corneocytes. Second, the transappendageal pathway includes penetration of solute through the shunt pathway created by the hair follicles and sweat glands.⁵⁵ As the transepidermal pathway favors drugs through the intercellular lipid domain present in the skin, lipophilic drug or carrier systems that have lipoidal properties are extensively explored. Conventional liposomes fail to permeate the skin barrier, deformable liposomes or flexible liposomes are being explored.⁵⁴ SLNs are initially explored for cosmetic and pharmaceutical dermal applications. Second generation NLC with higher drug loading capacity and stability proved a carrier system for cosmetic preparation and many finished cosmetic preparations are marketed all over the world. Drug delivery by NLC through the skin has yet to reach its full potential.⁵⁶

NLCs-based topical formulations result in deeper skin penetration and sustained drug release with less systemic side effects and skin irritation.^57–60 Various skin permeation enhancers can also be used to increase penetration of NLC in the skin.⁶¹ NLC also helps in decreasing wound healing time by delivering drugs at a sustained rate.^58,62 NLC enhances the drug delivery through increased skin permeation due to its smaller size. NLC due to the occlusive nature of small size particle increase hydration in the skin layer and elasticity which result in better drug permeation because of less water evaporation from the skin surface. NLC also provides stability and protection to a drug molecule. Deeper penetration of NLC into the skin layer results in slow drug release which gave a prolonged effect with less frequent application.⁸ Table 2 contains various examples of NLC which are delivered through the transdermal route.

Delivery through nasal route

Conventionally, nasal route is used to deliver drugs for the treatment of local conditions such as nasal congestion, rhinitis, sinusitis, and allergic condition. High drug permeability, high blood flow, comparability low enzymes, and ability to bypass first-pass metabolism result in a faster and higher drug delivery rate through this route. Due to easily accessible sites with the ability to deliver the drug directly to the brain bypassing the blood-brain barrier result in increased attention towards these routes of drug delivery for the nose to brain drug targetting.⁶⁷ Anatomically nasal cavity is divided into two chambers by the nasal septum. Among different regions of the nasal cavity respiratory and olfactory region is important for drug delivery. The respiratory region is rich in blood supply and drug delivery to the systemic circulation is indirectly achieved via the lungs.⁶⁸ Olfactory region contains olfactory receptor neurons, supporting cells, and basal cells. Drug delivery to the brain can be possible through nerves or through supporting cells via a transcellular pathway. There is another trigeminal pathway through which drugs can reach the brain quickly.⁶⁹

Certain limitations hinder the drug delivery through this route. Enzymatic degradation of a certain drug in the nasal cavity along with solubility and permeability are common problems associated with different routes also. One of the major hurdles is low contact or residence time of the drug due to rapid inward and outward drug flow and mucociliary clearance of the drug in regular intervals. Along with this, the sensitive nature of nasal mucosa creates local irritation if the drug is not isotonic and has different pH.⁷⁰

NLC are nanosized biocompatible carriers that can deeply penetrate nasal mucosa and show sustained drug release. With the ability to deliver the drug in the nasal mucosa, these carriers are frequently investigated to deliver the drug into the brain. As NLC have several advantages over conventional liposome and SLNs make them suitable carriers. Along with the inherent advantages, good stability and ability to be incorporated into various gelling and bioadhesives make them more effective in nasal drug delivery.^69,71 Management of various CNS-related conditions non-invasively such as glioblastoma, migraine, epilepsy, meningitis, etc along with quick delivery of the drug into the systemic circulation is possible through NLC.^31,71–74 Table 3 shows nasal application of drug delivery by NLC.

Delivery through parenteral route

The Parenteral Route is the most effective method of delivering drugs directly into the systemic circulation. It is the preferred route for the drug with a narrow therapeutic index and poor bioavailability. For emergency treatment of unconscious patients, the parenteral route is the only choice. One of the most discouraging characteristics of the parenteral route is injection of drug cause pain and discomfort with the need for assistance.⁷⁸ NLC has several advantages that make it a suitable carrier system for drug delivery. NLC can encapsulate water-insoluble lipophilic drugs to deliver them to the desired size. NLC showed a sustained drug release profile which reduces the injection frequency.^79,80 With surface modification, it is possible to target several organs and tumor cells. Which helps develop a safe and effective formulation of drugs with high toxicity and low therapeutic index. Employment of NLC is suitable for treating various carcinomas, infections, and diseases that involve targeting drugs to the brain such as neurodegenerative diseases.^80–84 Table 4 shows examples of NLC system which are delivered specifically by the parenteral route.

Delivery through ophthalmic route

The eye is one of the most sensitive and challenging organs for drug delivery. Drugs with low bioavailability or potential systemic toxicity which are needed for chronic ocular diseases like diabetic retinopathy, ocular infections, or other conditions which need long-term therapy are preferred for ocular drug delivery. Conventional ocular therapy needs frequent dosing which leads to patient discomfort.⁸⁵ Systemic administration of drugs for ophthalmic use is not preferred due to the blood ocular barrier. As the eye is exposed to the outer environment and is a sensitive organ several barriers make ocular delivery of drugs the most challenging task for formulators.⁸⁶

Anatomically eye is divided into two segments: The first anterior segment covering one-third part of the eye consists of cornea and lens assembly and the Second posterior segment covering a two-third portion of the eye consist of the retina and vitreous humor. There is a precorneal barrier, static barrier, and dynamic barrier due to the cornea, sclera, and retina making a blood-aqueous barrier and blood-retinal barrier.⁸⁷ Along with that surface removal of the drug due to lachrymal fluid secretion in the eye as well as blinking makes drug delivery difficult. Epithelial barrier on the outer corneal layer limits entry of hydrophilic drugs and macromolecules.⁸⁸

NLC is a promising carrier for ocular administration because of its biocompatible nature. Penetration in the eye is favored due to the small size, non-toxic, non-immunogenic, and lipidic nature of NLCs.⁸⁹ NLC formulation for ocular delivery contains a non-ionic surfactant. This formulation protects the drug from chemical degradation. Mucoadhesion along with small particle size act as a drug depot in the eye resulting in improved trans corneal diffusion and cellular uptake. Depot formation of NLC show sustained release of drug with less frequent administration.⁹⁰ Table 5 shows the employment of NLC based system for the delivery of drugs through the ophthalmic route.

NLC as a gene delivery system

Development in the field of medicine, biotechnology, and genetic engineering results in a better understanding of complex diseases and their treatment, which is not possible with the conventional approach. Delivery of RNA and DNA is explored for the treatment and immunization of genetic or acquired diseases. Direct transfer of genetic material in the cell is a difficult task because of the susceptibility of degradation, hydrophilic nature, and negative charge of this large size molecule. This challenging task of delivering genetic material can be accompanied by the utilization of vectors for gene delivery into cells.⁹⁴ Viral vectors are frequently used for gene transfection but due to the risk associated with a viral vector, a recently wide range of non-viral vectors are being explored.

Non-viral vectors show less immunogenicity, better flexibility, and low cytotoxicity. Target-specific gene delivery can be accomplished by non-viral surface and structural modification. Gold nanoparticles, carbon nanotubes, polymeric nanoparticles, liposomes, dendrimers, and SLNs are widely investigated for gene delivery. Lipid-based nanoparticles proved to better alternative due to better biocompatibility.⁹⁵ NLC being one of the lipid carriers with inherent advantages such as stability and better drug loading capacity than its counterpart draws the attention of researchers for gene delivery.

NLC can be incorporated into different formulations for the delivery of genetic material through different routes due to its relatively stable nature than other nano vectors.⁹⁶ Apart from systemic delivery of gene inhalation and transdermal route is also explored for the site-specific delivery and reduced toxicity as in lung cancer.^97,98 Mainly cationic lipid or positively charged nanocarriers are utilized but due to inherent cytotoxicity or nanotoxicity, thus further investigations are needed to make NLC an effective gene carrier.⁹⁹ Neutral NLC tends to show lower toxicity than cationic NLC.¹⁰⁰

A wide range of diseases like cancer and multi-drug resistant cancer, severe infections, AIDS, Alzheimer’s and Parkinson’s disease can be treated with the use of gene therapy.¹⁰¹ Gene therapy not only involves the delivery of DNA but also RNA for expression in a host cell, small interfering RNA (siRNA), messenger RNA (mRNA), and microRNA (miRNA) are the types of genes that are used in gene therapy. With the approval, of the COVID-19 vaccine based on lipid nanoparticles with enclosed mRNA, the gene delivery system is also being explored for the new future mRNA-based vaccine.¹⁰² Gene therapy and vaccination are different domains but due to the delivery of RNA in a host cell is involved we have summarized both in one section. Table 6 gives a brief account of the utilization of NLC for gene delivery.

Conclusion

NLCs are made possible by combining nanotechnology with lipids as a structural material. NLC are a versatile platform for drug delivery via various routes. These nanocarriers have drawn the interest of researchers from all over the world. Partially crystallized lipidic nanocarriers have high drug loading and stability than their predecessors such as liposomes, nanoemulsions, and SLNs. These nanocarriers are biodegradable, biocompatible, safe, and effective with high drug loading capacity. These nanocarriers can also be employed for active or passive drug targeting to different organs or tumor cells. NLC has proven its worth in the cosmetics industry, but its potential in the pharmaceutical industry has yet to be fully explored. NLC can be useful in diseases whose management is difficult, such as cancer, infections, neurodegenerative diseases, localized drug delivery as well as genetic diseases which conventional carrier systems cannot achieve. More research is required in this area to shift these interesting nanocarriers from lab to market. There is a need to evaluate the toxicity profile of such nanocarriers and solve the problems associated with nanomedicines such as complexity in formulation and characterization. Lack of sufficient clinical studies and data results in a slow development of these nanocarriers.

Competing Interests

None.

Ethical Approval

Not applicable.

References

1. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells NanomedBiotechnol 2016; 44(1):27-40. doi: 10.3109/21691401.2014.909822 [Crossref]
2. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci 2020; 7:587997. doi: 10.3389/fmolb.2020.587997 [Crossref]
3. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13(1):238-52. doi: 10.1016/s0022-2836(65)80093-6 [Crossref]
4. Advances and challenges of liposome assisted drug delivery. Front Pharmacol 2015; 6:286. doi: 10.3389/fphar.2015.00286 [Crossref]
5. Nanomedicines: the magic bullets reaching their target?. Eur J Pharm Sci 2019; 128:73-80. doi: 10.1016/j.ejps.2018.11.019 [Crossref]
6. Challenges and future prospects of nanoemulsion as a drug delivery system. Curr Pharm Des 2017; 23(3):495-508. doi: 10.2174/1381612822666161027111957 [Crossref]
7. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011; 8(3):207-27. doi: 10.2174/157016311796799062 [Crossref]
8. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv Pharm Bull 2020; 10(2):150-65. doi: 10.34172/apb.2020.021 [Crossref]
9. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine 2007; 2(4):595-607.
10. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel) 2021; 9(4):359. doi: 10.3390/vaccines9040359 [Crossref]
11. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018; 13(4):288-303. doi: 10.4103/1735-5362.235156 [Crossref]
12. Müller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles. In: Dragicevic N, Maibach HI, eds. Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Berlin, Heidelberg: Springer; 2016. p. 161-85. 10.1007/978-3-662-47862-2_11.
13. BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products. Beilstein J Nanotechnol 2019; 10:2152-62. doi: 10.3762/bjnano.10.208 [Crossref]
14. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009; 26(6):523-80. doi: 10.1615/critrevtherdrugcarriersyst.v26.i6.10 [Crossref]
15. Solid lipid nanoparticles as carriers of natural phenolic compounds. Antioxidants (Basel) 2020; 9(10):998. doi: 10.3390/antiox9100998 [Crossref]
16. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J 2021; 29(9):999-1012. doi: 10.1016/j.jsps.2021.07.015 [Crossref]
17. The effect of surfactant composition on the chemical and structural properties of nanostructured lipid carriers. J Microencapsul 2014; 31(6):609-18. doi: 10.3109/02652048.2014.911374 [Crossref]
18. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics 2020; 12(3):288. doi: 10.3390/pharmaceutics12030288 [Crossref]
19. Nanostructured lipid carriers: a review. J Dev Drugs 2018; 7(1):191. doi: 10.4172/2329-6631.1000191 [Crossref]
20. Nanostructured lipid carrier: the advanced lipid carriers. Int J Pharm Sci Res 2019; 10(12):5252-65. doi: 10.13040/ijpsr.0975-8232.10(12).5252-65 [Crossref]
21. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules 2020; 25(20):4781. doi: 10.3390/molecules25204781 [Crossref]
22. Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers. Drug Deliv 2020; 27(1):1054-62. doi: 10.1080/10717544.2020.1785050 [Crossref]
23. Nanostructured lipid carriers as a potential vehicle for carvedilol delivery: application of factorial design approach. Artif Cells NanomedBiotechnol 2016; 44(1):12-9. doi: 10.3109/21691401.2014.909820 [Crossref]
24. Biomimeting ultra-small lipid nanoconstructs for glioblastoma treatment: a computationally guided experimental approach. Int J Pharm 2020; 587:119661. doi: 10.1016/j.ijpharm.2020.119661 [Crossref]
25. Data on optimization and drug release kinetics of nanostructured lipid carriers containing ondansetron hydrochloride prepared by cold high-pressure homogenization method. Data Brief 2019; 26:104475. doi: 10.1016/j.dib.2019.104475 [Crossref]
26. Rifabutin-loaded nanostructured lipid carriers as a tool in oral anti-mycobacterial treatment of Crohn’s disease. Nanomaterials (Basel) 2020; 10(11):2138. doi: 10.3390/nano10112138 [Crossref]
27. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics 2019; 11(2):97. doi: 10.3390/pharmaceutics11020097 [Crossref]
28. Effect of high speed homogenizer speed on particle size of polylactic acid. J Phys Conf Ser 2019; 1198(6):062006. doi: 10.1088/1742-6596/1198/6/062006 [Crossref]
29. Olanzapine loaded nanostructured lipid carriers via high shear homogenization and ultrasonication. Sci Pharm 2021; 89(2):25. doi: 10.3390/scipharm89020025 [Crossref]
30. A hybrid genipin-crosslinked dual-sensitive hydrogel/nanostructured lipid carrier ocular drug delivery platform. Asian J Pharm Sci 2019; 14(4):423-34. doi: 10.1016/j.ajps.2018.08.002 [Crossref]
31. Application of computational tools for the designing of oleuropein loaded nanostructured lipid carrier for brain targeting through nasal route. Daru 2019; 27(2):695-708. doi: 10.1007/s40199-019-00304-0 [Crossref]
32. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 2017; 7(6):122. doi: 10.3390/nano7060122 [Crossref]
33. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 2014; 9:5449-60. doi: 10.2147/ijn.s73010 [Crossref]
34. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int J Pharm X 2021; 3:100074. doi: 10.1016/j.ijpx.2021.100074 [Crossref]
35. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig 2015; 5(4):182-91. doi: 10.4103/2230-973x.167661 [Crossref]
36. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug DelivTransl Res 2021; 11(2):471-97. doi: 10.1007/s13346-021-00908-7 [Crossref]
37. Oral delivery of proteins and peptides: challenges, status quo and future perspectives. Acta Pharm Sin B 2021; 11(8):2416-48. doi: 10.1016/j.apsb.2021.04.001 [Crossref]
38. The challenges of oral drug delivery via nanocarriers. Drug Deliv 2018; 25(1):1694-705. doi: 10.1080/10717544.2018.1501119 [Crossref]
39. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B 2013; 3(6):361-72. doi: 10.1016/j.apsb.2013.10.001 [Crossref]
40. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. Int J Nanomedicine 2019; 14:2267-80. doi: 10.2147/ijn.s194934 [Crossref]
41. Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. Pharmaceutics 2021; 13(11):1817. doi: 10.3390/pharmaceutics13111817 [Crossref]
42. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. J Nanobiotechnology 2018; 16(1):64. doi: 10.1186/s12951-018-0391-9 [Crossref]
43. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nat Commun 2016; 7:13184. doi: 10.1038/ncomms13184 [Crossref]
44. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artif Cells NanomedBiotechnol 2018; 46(sup2):616-25. doi: 10.1080/21691401.2018.1465068 [Crossref]
45. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments. Artif Cells NanomedBiotechnol 2018; 46(sup1):15-31. doi: 10.1080/21691401.2017.1408124 [Crossref]
46. Nanostructured lipid carriers (NLCs) for oral peptide drug delivery: about the impact of surface decoration. Pharmaceutics 2021; 13(8):1312. doi: 10.3390/pharmaceutics13081312 [Crossref]
47. Quetiapine fumarate loaded nanostructured lipid carrier for enhancing oral bioavailability: design, development and pharmacokinetic assessment. Curr Drug Deliv 2021; 18(2):184-98. doi: 10.2174/1567201817999200728135119 [Crossref]
48. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes. Eur J Pharm Sci 2017; 104:196-211. doi: 10.1016/j.ejps.2017.03.046 [Crossref]
49. Stabilized oral nanostructured lipid carriers of adefovir dipivoxil as a potential liver targeting: estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator. Daru 2020; 28(2):517-32. doi: 10.1007/s40199-020-00355-8 [Crossref]
50. Development and machine-learning optimization of mucoadhesive nanostructured lipid carriers loaded with fluconazole for treatment of oral candidiasis. Drug Dev Ind Pharm 2021; 47(2):246-58. doi: 10.1080/03639045.2020.1871005 [Crossref]
51. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. Int J Nanomedicine 2017; 12:8671-80. doi: 10.2147/ijn.s144615 [Crossref]
52. Topical administration of terpenes encapsulated in nanostructured lipid-based systems. Molecules 2020; 25(23):5758. doi: 10.3390/molecules25235758 [Crossref]
53. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv 2021; 11(46):29080-101. doi: 10.1039/d1ra06087b [Crossref]
54. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol 2015; 6:219. doi: 10.3389/fphar.2015.00219 [Crossref]
55. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J Pharm Sci 2017; 106(2):423-45. doi: 10.1016/j.xphs.2016.10.001 [Crossref]
56. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6):522-30. doi: 10.1016/j.addr.2007.04.012 [Crossref]
57. Tacrolimus-loaded lecithin-based nanostructured lipid carrier and nanoemulsion with propylene glycol monocaprylate as a liquid lipid: Formulation characterization and assessment of dermal delivery compared to referent ointment. Int J Pharm 2019; 569:118624. doi: 10.1016/j.ijpharm.2019.118624 [Crossref]
58. Nanostructured lipid carrier gel formulation of recombinant human thrombomodulin improve diabetic wound healing by topical administration. Pharmaceutics 2021; 13(9):1386. doi: 10.3390/pharmaceutics13091386 [Crossref]
59. Transdermal delivery system of nanostructured lipid carriers loaded with celastrol and indomethacin: optimization, characterization and efficacy evaluation for rheumatoid arthritis. Artif Cells NanomedBiotechnol 2018; 46(sup3):S585-S97. doi: 10.1080/21691401.2018.1503599 [Crossref]
60. Nanomaterial lipid-based carrier for non-invasive capsaicin delivery; manufacturing scale-up and human irritation assessment. Molecules 2020; 25(23):5575. doi: 10.3390/molecules25235575 [Crossref]
61. Development of pranoprofen loaded nanostructured lipid carriers to improve its release and therapeutic efficacy in skin inflammatory disorders. Nanomaterials (Basel) 2018; 8(12):1022. doi: 10.3390/nano8121022 [Crossref]
62. Nanophyto-gel against multi-drug resistant Pseudomonas aeruginosa burn wound infection. Drug Deliv 2021; 28(1):463-77. doi: 10.1080/10717544.2021.1889720 [Crossref]
63. Design and evaluation of lidocaine- and prilocaine-coloaded nanoparticulate drug delivery systems for topical anesthetic analgesic therapy: a comparison between solid lipid nanoparticles and nanostructured lipid carriers. Drug Des DevelTher 2017; 11:2743-52. doi: 10.2147/dddt.s141031 [Crossref]
64. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016; 11:5067-77. doi: 10.2147/ijn.s117511 [Crossref]
65. Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: formulation, optimization, characterization, in-vitro and in-vivo studies. Int J Nanomedicine 2020; 15:4763-78. doi: 10.2147/ijn.s247007 [Crossref]
66. Transcriptional transactivator peptide modified lidocaine-loaded nanoparticulate drug delivery system for topical anesthetic therapy. Drug Deliv 2016; 23(9):3193-9. doi: 10.3109/10717544.2016.1160459 [Crossref]
67. Nasal drug delivery system-an overview. Int J Res Pharm Sci 2010; 1(4):454-65.
68. A review on nasal drug delivery system and its contribution in therapeutic management. Asian J Pharm Clin Res 2019; 12(1):40-5. doi: 10.22159/ajpcr.2019.v12i1.29443 [Crossref]
69. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B 2021; 11(4):925-40. doi: 10.1016/j.apsb.2021.02.012 [Crossref]
70. Nasal drug delivery systems: an overview. Am J Pharmacol Sci 2015; 3(5):110-9.
71. Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme. Pharmaceutics 2020; 12(9):860. doi: 10.3390/pharmaceutics12090860 [Crossref]
72. Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule. J Pharm Sci 2020; 109(7):2237-51. doi: 10.1016/j.xphs.2020.04.007 [Crossref]
73. In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus. IET Nanobiotechnol 2020; 14(2):148-54. doi: 10.1049/iet-nbt.2019.0156 [Crossref]
74. Intranasal surface-modified mosapride citrate-loaded nanostructured lipid carriers (MOS-SMNLCs) for treatment of reflux diseases: in vitro optimization, pharmacodynamics, and pharmacokinetic studies. AAPS PharmSciTech 2018; 19(8):3791-808. doi: 10.1208/s12249-018-1142-9 [Crossref]
75. Development of carbamazepine nanostructured lipid carrier loaded thermosensitive gel for intranasal delivery. Adv Pharm Bull 2021; 11(1):150-62. doi: 10.34172/apb.2021.016 [Crossref]
76. Optimized nanostructured lipid carriers integrated into in situ nasal gel for enhancing brain delivery of flibanserin. Int J Nanomedicine 2020; 15:5253-64. doi: 10.2147/ijn.s258791 [Crossref]
77. Encapsulated escitalopram and paroxetine intranasal co-administration: in vitro/in vivo evaluation. Front Pharmacol 2021; 12:751321. doi: 10.3389/fphar.2021.751321 [Crossref]
78. Parenteral drug delivery: a review. Recent Pat Drug DelivFormul 2011; 5(2):133-45. doi: 10.2174/187221111795471391 [Crossref]
79. Preparation, pharmacokinetics, and antitumor potential of miltefosine-loaded nanostructured lipid carriers. Int J Nanomedicine 2021; 16:3255-73. doi: 10.2147/ijn.s299443 [Crossref]
80. Carvacrol loaded nanostructured lipid carriers as a promising parenteral formulation for leishmaniasis treatment. Eur J Pharm Sci 2020; 150:105335. doi: 10.1016/j.ejps.2020.105335 [Crossref]
81. Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. Drug Deliv 2020; 27(1):502-18. doi: 10.1080/10717544.2020.1745328 [Crossref]
82. Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. Daru 2017; 25(1):25. doi: 10.1186/s40199-017-0191-z [Crossref]
83. Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies. RSC Adv 2017; 7(27):16668-77. doi: 10.1039/c7ra00552k [Crossref]
84. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: an effective strategy to improve pharmacokinetics and reduce toxic effects. Biomed Pharmacother 2021; 144:112373. doi: 10.1016/j.biopha.2021.112373 [Crossref]
85. Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv Colloid Interface Sci 2021; 288:102342. doi: 10.1016/j.cis.2020.102342 [Crossref]
86. Nanotechnology for topical drug delivery to the anterior segment of the eye. Int J Mol Sci 2021; 22(22):12368. doi: 10.3390/ijms222212368 [Crossref]
87. Novel drug delivery systems for ocular therapy: with special reference to liposomal ocular delivery. Eur J Ophthalmol 2019; 29(1):113-26. doi: 10.1177/1120672118769776 [Crossref]
88. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010; 17(7):467-89. doi: 10.3109/10717544.2010.483257 [Crossref]
89. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective. Recent Pat Drug DelivFormul 2019; 13(4):246-54. doi: 10.2174/1872211314666191224115211 [Crossref]
90. Lipid-based nanocarriers for ophthalmic administration: towards experimental design implementation. Pharmaceutics 2021; 13(4):447. doi: 10.3390/pharmaceutics13040447 [Crossref]
91. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics 2020; 12(6):572. doi: 10.3390/pharmaceutics12060572 [Crossref]
92. Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. Pharmaceutics 2021; 13(6):905. doi: 10.3390/pharmaceutics13060905 [Crossref]
93. Ocular formulation based on palmitoylethanolamide-loaded nanostructured lipid carriers: technological and pharmacological profile. Nanomaterials (Basel) 2020; 10(2):287. doi: 10.3390/nano10020287 [Crossref]
94. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 2009; 11(4):671-81. doi: 10.1208/s12248-009-9143-y [Crossref]
95. Recent advances in nanomaterials for gene delivery-a review. Nanomaterials (Basel) 2017; 7(5):94. doi: 10.3390/nano7050094 [Crossref]
96. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015; 217:345-51. doi: 10.1016/j.jconrel.2015.08.007 [Crossref]
97. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics 2019; 9(26):8362-76. doi: 10.7150/thno.39816 [Crossref]
98. Collagen scaffold-mediated delivery of NLC/siRNA as wound healing materials. J Drug Deliv Sci Technol 2020; 55:101421. doi: 10.1016/j.jddst.2019.101421 [Crossref]
99. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) 2014; 9(2):295-312. doi: 10.2217/nnm.13.204 [Crossref]
100. Nanostructured lipid carriers for microRNA delivery in tumor gene therapy. Cancer Cell Int 2018; 18:101. doi: 10.1186/s12935-018-0596-x [Crossref]
101. Recent advances in the development of gene delivery systems. Biomater Res 2019; 23:8. doi: 10.1186/s40824-019-0156-z [Crossref]
102. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 2021; 15(11):16982-7015. doi: 10.1021/acsnano.1c04996 [Crossref]
103. Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv 2016; 23(4):1369-73. doi: 10.3109/10717544.2015.1038857 [Crossref]
104. A nanostructured lipid carrier for delivery of a replicating viral rna provides single, low-dose protection against Zika. Mol Ther 2018; 26(10):2507-22. doi: 10.1016/j.ymthe.2018.07.010 [Crossref]
105. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug DelivTransl Res 2020; 10(3):646-60. doi: 10.1007/s13346-020-00723-6 [Crossref]
106. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine 2017; 13(6):1983-92. doi: 10.1016/j.nano.2017.04.005 [Crossref]
107. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine 2015; 10:1223-33. doi: 10.2147/ijn.s77837 [Crossref]